| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9191231 | Epilepsy Research | 2005 | 9 Pages |
Abstract
Add-on therapy of lamotrigine for patients with uncontrolled epilepsy offers improved health outcomes. Lamotrigine therapy is associated with increased cost (â¬453) and an annual incremental cost-effectiveness ratio of â¬954. These data, together with utility data published in the literature, support the notion that lamotrigine should be considered as an add-on therapy in for patients with refractory epilepsy.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
P.D. Knoester, A.J. Boendermaker, A.C.G. Egberts, Y.A. Hekster, A. Keyser, J.L. Severens, W.O. Renier, C.L.P. Deckers,